A1 Refereed original research article in a scientific journal

Median 10-year whole blood metal ion levels and clinical outcome of ReCap-M2a-Magnum metal-on-metal total hip arthroplasty




AuthorsPietiläinen Sakari, Linnovaara Axel, Venäläinen Mikko S, Mäntymäki Heikki, Laaksonen Inari, Lankinen Petteri, Mäkelä Keijo T

PublisherMedical Journals Sweden AB

Publication year2022

JournalActa Orthopaedica

Journal name in sourceActa Orthopaedica

Volume93

First page 444

Last page450

eISSN1745-3674

DOIhttps://doi.org/10.2340/17453674.2022.2510

Web address https://doi.org/10.2340/17453674.2022.2510

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/175280095


Abstract

Background and purpose

We have previously reported that the whole blood (WB) chromium (Cr) and cobalt (Co) ion levels decrease in the short term after ReCap-M2a-Magnum large-diameter head (LDH) metal-on-metal (MoM) total hip arthroplasty (THA). This study reports long-term metal ion levels and clinical outcomes after ReCap-Magnum THA.

Patients and methods

ReCap-M2a-Magnum LDH THA was used in 1,450 patients in our hospital district from 2005 to 2012. Median follow-up time was 10 years. 991 patients had 2 or more metal ion measurements. The median measurement interval was 4 years. Individual metal ion change was assessed using logarithmic metal ion values in a random coefficient model. Kaplan–Meier survival estimates were calculated for revision surgery for any reason for revision, and separately for metal-related adverse events (metal
ions above safe upper limit [SUL], revision due to ARMD, or pseudotumor).

Results

Geometric mean of Cr decreased from 1.8 ppb (geometric standard deviation [GSD] 1.8) to 1.0 ppb (GSD 2.8, p < 0.001). The Co levels decreased from 1.7 ppb (GSD 2.4) to 1.4 ppb (GSD 2.8, p < 0.001). The hip-specific survival was 85% for revision due to any reason at 14 years and the hip-specific survival for any metal-related adverse event was 69% at 14 years.

Interpretation

WB Cr and Co levels continued to decrease in the long-term follow-up of ReCap-M2a-Magnum THA patients. The amount of metal-related adverse events was rather high, but revision surgery was seldom required. We suggest that after 10 years from the implantation a 5-year measurement interval may be sufficient for asymptomatic ReCap-M2a-Magnum patients.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 20:52